Month: March 2012

We are here live at the Fourth BHD Symposium, at the University of Cincinnati. The University of Cincinnati has not only been called one of the world’s most beautiful campuses (by Forbes magazine), but also has an illustrious history in medical research, including the development of the first antihistamine and the first oral polio vaccine. … Read more

The Fourth BHD Symposium is less than a week away, and this year it will be held in Cincinnati, USA, on 28th to 30th March. Registration is still open and more information regarding the entire Symposium can be found here. In particular, the Fourth BHD Symposium agenda and Patient and family sessions schedule are now available. There will … Read more

Recent advances in DNA sequencing have led to the discovery of genes and mutations which drive tumourigenesis. In this blog, we have previously described papers by Varela et al. (2011), Dalgliesh et al. (2011) and Guo et al. (2011) which all used exome sequencing to identify genes involved in kidney cancer (described here, here and … Read more

Our lab-profile for this month introduces the work of Professor Arnim Pause, an Associate Professor in the Department of Biochemistry and a Canada Research Chair in Molecular Oncology at McGill University, Canada. Much of Professor Pause’s early work involved researching eukaryotic translation initiation factors, such as eIF-4A and eIF-4E, which play an important role in … Read more

Hypoxia Inducible Factor (HIF) regulates key processes within the cell and its dysregulation is involved in the development of renal cell carcinoma (RCC), including those associated with VHL, HLRCC, TSC and also BHD syndrome. HIF is a potential therapeutic target for RCC and examples of HIF inhibitors have been described in this previous blog. Despite … Read more